Research and Markets: Investigation Report on China's Anastrozole Market, 2010-2019

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/kplb5z/investigation) has announced the addition of the "Investigation Report on China's Anastrozole Market, 2010-2019" report to their offering.

As a non-steroidal aromatase-inhibiting, anastrozole works by inhibiting the synthesis of estrogen in post- menopausal women which can increase the severity of breast cancer. Besides, anastrozole has little influence on adrenocortical steroid or aldosterone.

Originally developed by AstraZeneca, anastrozole was approved by the FDA as the second-line medicine for breast cancer in 1995 and later in 2000 became the first-line drug. In 2002, it was approved as the therapy for postmenopausal women with localized breast cancer which is ER positive.

The incidence of breast cancer has kept growing since the 1970s in the world. With decreasing fertility rate, environmental changes, increasing pressure and growing number of women aged 50-54 who face greater risk of breast cancer, the incidence of breast cancer in China grows at a rate which is 1-2% higher than that in other countries and doubles that of the world average. As the malignant tumor with the highest incidence, breast cancer will report 2.5 million cases by 2021 in China. Hence a huge market for anastrozole.

The demand for anastrozole is gradually growing. According to this market survey, anastrozole sales has went up slightly to CNY 184 million in 2014 with CAGR during the period of 2010-2014 reaching 4.89%. And AstraZeneca (US), Yangtze River Pharmaceutical Group, Huapont Pharm, Wanma Group and Hisun occupy the market, among of which AstraZeneca (US) had the largest market share of about 92% for sales value in 2014.

Key Topics Covered:

1 Related Concepts of Anastrozole

2 Market Profile of Anastrozole in China

3 Survey on Anastrozole Sales in China, 2010-2014

4 Survey on Market Share of Major Anastrozole Manufacturers in China, 2010-2014

5 Survey on Dosage Forms of Anastrozole in China, 2010-2014

6 Reference Price of Anastrozole in Chinese Hospitals in 2014

7 Major Manufacturers of Anastrozole in Chinese Market, 2010-2014

8 Market Outlook of Anastrozole in China, 2015-2019

Companies Mentioned

- AstraZeneca

- Huapont Pharm

- Wanma Group

- Yangtze River Pharmaceutical Group

- Zhejiang Hisun Pharmaceutical Co.,Ltd.

For more information visit http://www.researchandmarkets.com/research/kplb5z/investigation

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals